Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06240546 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

StatusRecruiting
PhasePhase 1
Started2024-03-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 15, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2024-03-12
Not Yet Recruiting→Recruiting Study Status, Study Design, Arms and Interventions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-02→confirmed 2024-03-12
Study sites0→1
Study arms1→7
2024-02-27
Study Status, Study Design v1
Re-verified, no change to tracked fields
2024-01-26
Original filing
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.
Trial Details
NCT Number NCT06240546
Lead Sponsor Luye Pharma Group Ltd.
Conditions Advanced Solid Tumor
Enrollment 102 participants
Start Date 2024-03-12
Primary Completion 2026-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-03-15